QurAlis Corp.

World-renowned leaders to explore clinical, preclinical and investment landscapes for Alzheimer's and other diseases with a focus on novel hypotheses and clinical diversity CAMBRIDGE, Mass., Oct. 10, 2024 /PRNewswire/ -- LabCentral, the premier Massachusetts-based network of coworking labs designed to accelerate high-potential biotech startups, today announced the new Mind Matters Scientific Symposium which will be held on Tuesday, November 12, 2024. The inaugural full-day event, dedicated to the newest approaches and challenges in the neurodegenerative space, will feature keynotes and panel conversations with leading experts across the preclinical, clinical and investment sectors of the Alzheimer's and neurodegenerative disease communities, including Dr. Beth Hoffman (Origami); Prof. Dennis Selkoe (HMS); Prof. Li-Huei Tsai (MIT); Dr. Dan Elbaum (QurAlis); Dr. Ricardo Dolmetsch (Curie Bio), and others. "As the leading space for life-sciences startups, elevating the critical issues and latest developments in translational science is critical for our residents and the broader ecosystem," said Johannes Fruehauf, MD, PhD, CEO and cofounder of LabCentral. "We're honored that this esteemed group from across the industry and academia is joining us in the conversation on this critical topic to share their findings and insights." Supported by Bayer, the Symposium is designed for the translational sciences community - researchers, industry professionals, investors and others - interested in learning more about transformative discoveries. Throughout the day, keynotes and panels will address scientific breakthroughs in different neurodegenerative diseases, including Alzheimer's, Parkinson's and Amyotrophic lateral sclerosis (ALS), with a focus on novel hypotheses and ensuring clinical diversity. The Symposium will also feature a curated poster session and networking reception hosted by Bayer to conclude the day. Researchers interested in submitting a poster should submit their abstracts here. On the day of the symposium judges will select the winning poster presentation to receive the award and a $300 gift card. With limited space, Symposium registrations are available for in-person or virtual attendance. Members of the press interested in attending should reach out to Allison Parker at LabCentral. Prospective attendees should contact Sezin Yigit. More information on the agenda and topics can be found at the event website. Some of the sessions will include: Planning and Executing Effective Clinical Trials for AD(RD) Research Technical Insights and Future Directions for Alzheimer's Clinical Trials Molecular Mechanisms and Therapeutic Targets in Alzheimer's Disease APOE4, Neurodegeneration, and Therapeutic Innovation in Alzheimer's Research Panel: Drug Discovery Strategies and Innovations in Neurodegenerative Diseases About LabCentral A private, non-profit institution, LabCentral is a launchpad for high potential life-sciences and biotech startups with 243,000 square feet of space across Kendall Square in Cambridge, Mass., and the Harvard University campus. Founded in 2013, LabCentral offers a full complement of programming and networking to life sciences entrepreneurs in addition to fully permitted laboratory and office space for early-stage and growing life sciences companies. Our 10-year Impact Report can be found here, and additional information is available at . Media Contact: Doug Broad, [email protected] SOURCE LabCentral WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

QRL-101 is the only Kv7.2/7.3 ion channel opener being actively studied for the treatment of hyperexcitability-induced disease progression in ALS Kv7.2/7.3 is a clinically validated target to regulate the hyperexcitable state in epilepsy Company initiates exploratory Phase 1 proof-of-mechanism study in healthy volunteers to characterize the potential anti-seizure effects of QRL-101 CAMBRIDGE, Mass., September 19, 2024 – QurAlis Corporation (“QurAlis”), a clinical-stage biotechnology company driving scientific breakthroughs into powerful precision medicines that have the potential to alter the trajectory of amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), and other neurodegenerative and neurological diseases, today announced that the company is expanding its Kv7 development program to include epilepsy. The Company’s lead investigational candidate, QRL-101 is the only Kv7.2/7.3 ion channel opener being actively studied for the treatment of hyperexcitability-induced disease progression in ALS, which is present in approximately 50 percent of ALS patients. Kv7 is a clinically validated target to regulate the hyperexcitable state in epilepsy. QurAlis also announced the initiation of an exploratory Phase 1 proof-of-mechanism electroencephalogram biomarker study in healthy volunteers of QRL-101 to characterize the potential anti-seizure effects of QRL-101. “Epilepsy, one of the most common and most disabling neurological seizure disorders, is characterized by spontaneous recurrent seizures, which disrupt normal brain functions, lead to neuronal loss, and result in cognitive and emotional deficits. In about one-third of people living with epilepsy, the seizures are resistant to current treatments; so more effective treatments are urgently needed,” said Kasper Roet, Ph.D., chief executive officer and co-founder of QurAlis. “QRL-101, is a highly selective Kv7.2/7.3 ion channel opener, which in preclinical models shows a strong potential to control motor neuron hyperexcitability-induced neurodegeneration with an attractive side effect profile. Since Kv7 is a clinically validated target in controlling hyperexcitability in epilepsy, we are excited to expand our scope of QRL-101 into a new therapeutic area and explore the potential of QRL-101 in epilepsy so that QurAlis can continue the goal of making a real difference in patients’ lives.” About Kv7 Kv7.2/7.3 is a voltage-gated potassium channel whose role is crucial for the regulation of neuronal excitability and membrane potential. The activation of this channel shows the potential to decrease spinal and cortical motor neuron excitability and to positively affect several electrophysiological biomarkers. This suggests that this may be an effective therapeutic approach in several neurodegenerative and neurological diseases including ALS and epilepsy. About Epilepsy Epilepsy is one of the most common chronic neurological diseases and, according to the Centers for Disease Control, affects more than 65 million people around the world of which 3.4 million are in the U.S. Epilepsy is characterized by unpredictable, recurrent seizures, which are brief episodes of involuntary movement that may involve a part of the body (partial) or the entire body (generalized). Seizure episodes are a result of excessive electrical discharges in a group of brain cells. According to the World Health Organization, recurrent seizures disrupt normal brain functions, lead to neuronal loss, and result in cognitive and emotional deficits. Patients suffer from stigmatization, social isolation, combined with disability, educational underachievement, and poor employment outcomes. The Epilepsy Foundation estimates that one-third of people with epilepsy live with uncontrollable seizures because no available treatments are effective. About QurAlis Corporation At QurAlis, we are neuro pioneers on a quest to cure. We work with a relentless pursuit of knowledge, a precise attention to craft, and an optimistic mindset to discover and develop effective precision medicines that have the potential to alter the trajectory of amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), and other neurodegenerative and neurological diseases. Founded by an internationally recognized team of neurodegenerative biologists from Harvard Medical School and Harvard University, QurAlis is advancing a robust precision medicine pipeline with therapeutic candidates aimed at modifying severe disease pathology in defined patient populations based on both disease-causing genetic mutation(s) and clinical biomarkers. For more information, please visit www.quralis.com or follow us on X @QurAlisCo or LinkedIn.

QRL-101 aims to reduce hyperexcitability-induced neurodegeneration, which is present in approximately 50 percent of all ALS patients Completed Phase 1 single-ascending dose (SAD) clinical trial of QRL-101 enrolled 88 participants; no reported significant safety concerns or serious adverse events MAD data expected to be reported in first half of 2025; results will support larger global studies in people living with ALS CAMBRIDGE, Mass., Sept. 10, 2024 /PRNewswire/ -- QurAlis Corporation ("QurAlis"), a clinical-stage biotechnology company driving scientific breakthroughs into powerful precision medicines that have the potential to alter the trajectory of amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), and other neurodegenerative and neurological diseases, today announced that the company recently completed dosing of the first participant cohort in the Phase 1 multiple-ascending dose (MAD) clinical trial evaluating QRL-101 (QRL-101-03; NCT06532396). QRL-101 is a first-in-class selective Kv7.2/7.3 ion channel opener for the treatment of hyperexcitability-induced disease progression in ALS. Kv7.2 is a mis-spliced protein in sporadic ALS patients. QRL-101-03 is a randomized, double-blind, placebo-controlled, single-site Phase 1 clinical trial designed to evaluate the safety, tolerability, and pharmacokinetics of multiple-ascending doses of QRL-101 in adult healthy volunteers. The study is expected to enroll approximately 60 participants, who will be randomized in a 9:3 ratio of QRL-101 to placebo into five planned cohorts. The dose range of QRL-101 for this MAD study was determined by results from QurAlis' Phase 1 single-ascending dose (SAD) clinical trial (QRL-101-01; NCT05667779). Of the 88 healthy participants in the SAD clinical trial, no significant safety concerns or serious adverse events have been reported for QRL-101. "We are excited to complete dosing of our first participant cohort in our Phase 1 MAD clinical trial of QRL-101. In the SAD study, QRL-101 was shown to be well tolerated, with no significant safety concerns or serious adverse events," said Doug Williamson, M.D., chief medical officer of QurAlis. "ALS is a devastating, fatal neurodegenerative disease and there are currently no therapies that can significantly extend patients' lives. QRL-101 has the potential to be a first-in-class effective therapy for ALS patients suffering from hyperexcitability-induced motor neuron degeneration. We look forward to advancing the clinical program for QRL-101 so QurAlis can bring much-needed therapies to people living with ALS." "Motor system hyperexcitability occurs in approximately 50 percent of all ALS patients and is linked to potassium channel dysfunction," said Leonard H. van den Berg, M.D., Ph.D., professor of neurology and chair, TRICALS. "QRL-101, is a highly selective Kv7.2/7.3 ion channel opener, which in preclinical models shows a strong potential to control motor neuron hyperexcitability-induced neurodegeneration with an attractive side effect profile. We are encouraged by the findings from the SAD study of QRL-101 and look forward to results from the MAD study." QurAlis anticipates reporting topline data from the Phase 1 MAD clinical trial of QRL-101 in the first half of 2025. More information about the QRL-101 Phase 1 clinical trials can be found at . About Amyotrophic Lateral Sclerosis (ALS) Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease, is a progressive neurodegenerative disease impacting nerve cells in the brain and spinal cord, reducing muscle function and control. ALS can be traced to mutations in more than 25 different genes and is often caused by a combination of multiple sub-forms of the condition. Cases usually cannot be predicted, although a small percentage are inherited. ALS has a devastating impact on patients and families. ALS patients' average life expectancy is three years; after diagnosis patients only have two years to live. There is currently no cure for the disease. About Kv7 Kv7.2/7.3 is a voltage-gated potassium channel whose role is crucial for the regulation of neuronal excitability and membrane potential. Kv7.2 is mis-spliced in sporadic ALS leading to loss of function and abnormal electrical activity in the spinal cord and brain. The activation of this channel shows the potential to decrease spinal and cortical/motor neuron excitability and to positively affect CMAP (compound muscle action potential). This suggests that this may be an effective therapeutic approach for ALS patients suffering from hyperexcitability-induced motor neuron degeneration. About QurAlis Corporation At QurAlis, we are neuro pioneers on a quest to cure. We work with a relentless pursuit of knowledge, a precise attention to craft, and an optimistic mindset to discover and develop effective precision medicines that have the potential to alter the trajectory of amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), and other neurodegenerative and neurological diseases. Founded by an internationally recognized team of neurodegenerative biologists from Harvard Medical School and Harvard University, QurAlis is advancing a robust precision medicine pipeline with therapeutic candidates aimed at modifying severe disease pathology in defined patient populations based on both disease-causing genetic mutation(s) and clinical biomarkers. For more information, please visit or follow us on X @QurAlisCo or LinkedIn. SOURCE QurAlis